AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021
February 16 2021 - 8:00AM
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a
biotechnology company conducting human clinical trials of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare diseases, today announced that Dave Knop, Vice President of
Process Development, and Jill Dolgin, PharmD, Executive
Director of Patient Advocacy, will present at the 4th Annual Gene
Therapy for Rare Disorders digital event taking place February
22-25, 2021.
Dr. Knop will lead a pre-conference workshop, “Unifying Process
& Analytical Development to Establish Robust, Scalable Gene
Therapy Manufacturing Processes” on Monday, February 22 from 1:00 –
4:00 PM EST.
“With an increasing number of gene therapies moving toward
approval, manufacturing continues to be a critical component of
success with respect to safety, regulatory approval and commercial
viability,” said Dr. Knop. “The goal of the workshop is to share
insights into the configuration of scalable gene therapy processes
designed to pre-emptively overcome challenges to manufacturing for
commercial markets.”
Dr. Dolgin will join a panel of patient advocacy experts,
“Channeling Patient Input: Industry & Patient Advocacy
Perspectives” at 3:30 PM EST on Wednesday, February 24.
“Engagement with patients and caregivers is a critical success
factor in enhancing our understanding of retinal disorders, guiding
clinical trial design, and inspiring our patient-centric culture,”
said Dr. Dolgin, “I look forward to joining the other panel members
to discuss our perspectives and what we can do to address the
issues that are meaningful to patients as we develop and advance
our product-development initiatives.”
To learn more about the event and registration, please visit:
https://genetherapy-conference.com/.
About AGTCAGTC is a clinical-stage
biotechnology company developing genetic therapies for people with
rare and debilitating ophthalmic, otologic and central nervous
system (CNS) diseases. AGTC is a leader in designing and
constructing all critical gene therapy elements and bringing them
together to develop customized therapies that address real patient
needs. AGTC’s most advanced clinical programs leverage its
best-in-class technology platform to potentially improve vision for
patients with an inherited retinal disease. AGTC has active
clinical trials in X-linked retinitis pigmentosa (XLRP) and
achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its preclinical
programs build on the Company’s industry-leading AAV manufacturing
technology and scientific expertise. AGTC is advancing multiple
important pipeline candidates to address substantial unmet clinical
need in optogenetics, otology and CNS disorders.
IR/PR Contacts:David Carey (IR)
or Glenn Silver (PR)Lazar FINN PartnersT: (212) 867-1768
or (646) 871-8485david.carey@finnpartners.com or
glenn.silver@finnpartners.com
Corporate Contacts:Bill SullivanChief Financial
OfficerApplied Genetic Technologies CorporationT: (617)
843-5728bsullivan@agtc.com
Stephen PotterChief Business OfficerApplied Genetic Technologies
CorporationT: (617) 413-2754spotter@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2024 to May 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From May 2023 to May 2024